bioAffinity Technologies prices $4M ATM private placement with warrants
bioAffinity Technologies (BIAF) prices a ~$4.0M-at-gross private placement at-the-market selling 8.46M shares (or pre-funded warrants) plus warrants for up to 16.9M more shares, with warrants struck at $0.4727.
BIAF bioAffinity Technologies prices $4M private placement at-the-market — Biotech/Diagnostics — Selling 8.46M shares (or pre-funded warrants) plus warrants for up to 16.9M more shares — Combined effective price of $0.4727 per share and warrant package — Warrants carry a $0.4727 strike, exercisable after shareholder approval, five-year term — Gross proceeds ~$4.0M before fees — Expected to close August 14 — Company's lead product is CyPath Lung, a noninvasive early-stage lung cancer detection test